BlackRock Fund Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

BlackRock Fund Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$40.5M	Buy	2,146,963 +115,227	+6%	+$2.82M	0.01%	1814
2016 Q3	$61M	Buy	2,031,736 +67,333	+3%	+$2.09M	0.01%	1437
2016 Q2	$75.5M	Buy	1,964,403 +446,978	+29%	+$18.6M	0.02%	1202
2016 Q1	$57.8M	Buy	1,517,425 +187,826	+14%	+$6.54M	0.01%	1355
2015 Q4	$58.5M	Buy	1,329,599 +1,182,852	+806%	+$58.7M	0.01%	1373
2015 Q3	$5.97M	Buy	146,747 +54,843	+60%	+$2.41M	﹤0.01%	2694
2015 Q2	$4.9M	Buy	91,904 +15,001	+20%	+$796K	﹤0.01%	2936
2015 Q1	$4.67M	Buy	+76,903	New	+$3.73M	﹤0.01%	2879

Other funds holding JUNO

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock Fund Advisors's JUNO Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Juno Therapeutics, Inc. (JUNO) stake by 5.7% in Q4 2016, buying an estimated $2.82M and bringing the position to 2,146,963 shares worth $40.5M. The position accounts for 0.01% of the portfolio, ranked #1814.

BlackRock Fund Advisors first reported a position in JUNO in Q1 2015 and has held it in 8 quarters since. The position peaked at $75.5M in Q2 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

BlackRock Fund Advisors held 2,146,963 shares of Juno Therapeutics, Inc. worth $40.5M as of Q4 2016.
BlackRock Fund Advisors bought 115,227 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $2.82M.
Juno Therapeutics, Inc. made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1814 holding.
BlackRock Fund Advisors first reported a position in Juno Therapeutics, Inc. in Q1 2015 and has held it in 8 quarters since.
BlackRock Fund Advisors's Juno Therapeutics, Inc. position peaked at $75.5M in Q2 2016.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.